| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 2mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
The specific molecular target of 5,6-Epoxyergosterol has not been well-characterized. As a sterol derivative, it may interact with cellular membranes and modulate their properties. Epoxy sterols are known to have various biological activities, including antifungal, cytotoxic, and anti-inflammatory effects. The compound's mechanism of action may involve disruption of membrane integrity, inhibition of specific enzymes, or modulation of signaling pathways. Further research is needed to identify its primary targets and mechanism of action.
|
|---|---|
| ln Vitro |
In vitro activity of 5,6-Epoxyergosterol has not been extensively reported. As a natural product isolated from an endophytic fungus, it is presumed to possess biological activities. Ergosterol derivatives are often studied for their antifungal properties, as ergosterol is a major component of fungal cell membranes. The epoxide group may confer additional reactivity and biological activity. However, specific in vitro data, such as IC50 values against specific cell lines or microorganisms, are not available in the literature.
|
| ln Vivo |
In vivo activity data for 5,6-Epoxyergosterol is not available in the literature. As a natural product, its effects in living organisms have not been characterized. It is likely that the compound would need to be evaluated in animal models to determine its efficacy and safety profile for any potential therapeutic application. Its structural similarity to other sterols suggests it may have biological effects, but specific studies are lacking.
|
| Enzyme Assay |
In vitro enzyme/receptor binding (non-cell) assays for 5,6-Epoxyergosterol are not documented. For sterol compounds, a general approach to study their activity is to assess their effects on membrane fluidity and integrity using model membrane systems such as liposomes. The compound could be incorporated into liposomes, and its effects on membrane permeability and stability could be measured using fluorescent dyes. Additionally, its ability to inhibit enzymes involved in sterol metabolism (e.g., sterol 14α-demethylase) could be assessed using biochemical assays.
|
| Cell Assay |
In vitro cell-based assays for 5,6-Epoxyergosterol have not been specifically reported. For similar sterol compounds, a common protocol involves culturing cancer cell lines (e.g., HeLa, MCF-7, or A549) and treating them with various concentrations of the compound for 24-72 hours. Cell viability is assessed using the MTT or SRB assay. Additionally, the compound's effects on cell cycle progression and apoptosis can be evaluated using flow cytometry. Antifungal activity can be assessed using broth microdilution assays against various fungal strains. Specific results for 5,6-Epoxyergosterol are not available.
|
| Animal Protocol |
In vivo animal experiments for 5,6-Epoxyergosterol have not been described. For natural products with potential anticancer or antifungal activity, in vivo studies would involve using mouse models of cancer or fungal infection. For example, tumor-bearing mice could be treated with the compound, and tumor growth would be monitored. For antifungal activity, a mouse model of systemic candidiasis could be used. Such studies have not been reported for this compound.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 5,6-Epoxyergosterol have not been characterized. The compound is a sterol with a molecular weight of 412.65 g/mol and is expected to be lipophilic. It is likely to be soluble in organic solvents such as chloroform, dichloromethane, and DMSO. Its absorption, distribution, metabolism, and excretion are unknown. The epoxide functional group may be metabolized by epoxide hydrolases, and the compound may undergo further metabolism via oxidation or conjugation.
|
| Toxicity/Toxicokinetics |
Toxicity data for 5,6-Epoxyergosterol is not available. As a natural product, its safety profile has not been evaluated. The presence of the epoxide group, which can be reactive and potentially genotoxic, suggests that caution should be exercised when handling the compound. Standard laboratory safety precautions should be followed. The compound is intended for research use only and not for human consumption.
|
| References | |
| Additional Infomation |
5α,6α-Epoxy-24(R)-Methylcholest-7,22-dien-3β-ol is an ergosterol compound. It has been reported that Cordyceps sinensis contains 5,6-epoxyergosterol, and relevant data are available for reference.
5,6-Epoxyergosterol is a natural product isolated from the endophytic fungus Phyllosticta capitalensis. It is an epoxy sterol with a characteristic epoxide group at the 5 and 6 positions. The compound is a member of the ergosterol family and is of interest for its potential biological activities. It is not a drug and has no clinical use or approval status. It is commercially available from chemical suppliers for research purposes only. |
| Molecular Formula |
C28H44O2
|
|---|---|
| Molecular Weight |
412.64776
|
| Exact Mass |
412.334
|
| CAS # |
23637-31-2
|
| PubChem CID |
100938000
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
513.6±50.0 °C at 760 mmHg
|
| Flash Point |
210.6±24.4 °C
|
| Vapour Pressure |
0.0±3.0 mmHg at 25°C
|
| Index of Refraction |
1.551
|
| LogP |
7.74
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
30
|
| Complexity |
752
|
| Defined Atom Stereocenter Count |
10
|
| SMILES |
CC(C)C(C)C=CC(C)C1CCC2C1(CCC3C2=CC4C5(C3(CCC(C5)O)C)O4)C
|
| InChi Key |
KVMYKLHJBYIOKD-QYYFJRRUSA-N
|
| InChi Code |
InChI=1S/C28H44O2/c1-17(2)18(3)7-8-19(4)22-9-10-23-21-15-25-28(30-25)16-20(29)11-14-27(28,6)24(21)12-13-26(22,23)5/h7-8,15,17-20,22-25,29H,9-14,16H2,1-6H3/b8-7+/t18-,19+,20-,22+,23-,24-,25-,26+,27+,28-/m0/s1
|
| Chemical Name |
(1S,2R,5S,7R,9S,12R,15R,16R)-15-[(E,2R,5R)-5,6-dimethylhept-3-en-2-yl]-2,16-dimethyl-8-oxapentacyclo[9.7.0.02,7.07,9.012,16]octadec-10-en-5-ol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4234 mL | 12.1168 mL | 24.2336 mL | |
| 5 mM | 0.4847 mL | 2.4234 mL | 4.8467 mL | |
| 10 mM | 0.2423 mL | 1.2117 mL | 2.4234 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
